

## EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma

KYRIAKI TZOGANI, PAULA VAN HENNIK, ITA WALSH, PIETER DE GRAEFF, ANNIKA FOLIN, JAN SJÖBERG, TOMAS SALMONSON, JONAS BERGH, EDWARD LAANE, HEINZ LUDWIG, CHRISTIAN GISSELBRECHT, FRANCESCO PIGNATTI

*The Oncologist* 2018;23:631–636; first published on November 30, 2017; <http://dx.doi.org/10.1634/theoncologist.2017-0301>

A correction was made to a sentence in the Clinical Safety section of this article to clarify the names of the two arms being compared. The online version of this article was updated, and the corrected sentence reads as follows:

More patients required hospitalization due to AEs in the PAN + BTZ + Dez arm (55%) than in the PBO + BTZ + Dex arm (37%).